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Old problems and new developments in the 
fight against the major tropical diseases 
(Joint Symposium with the World Health 
Organisation) 
Novel Approaches to New Drug Targets in 
Protozoan Parasites 
D.E Wirth. Harvard University, Boston, MA, USA 
Parasitic diseases remain a major threat to world health today and 
with the emergence and spread of drug resistance, represent an in- 
creasing threat throughout the world. Yet, drugs for these diseases 
are based on a s m a l l  number of old lead compounds and hence there 
is an urgent need for identification of new targets for drug discovery 
and development. Recent advances in techniques for molecular ge- 
netic analysis and parasitic genome initiatives, including the Malaria 
Genome Sequencing consortium, provide an opportunity to rapidly 
idenhfy and evaluate key metabolic enzymes as potential drug tar- 
gea. These strategies and recent examples of target identification 
will be reviewed. Examples of targets under investigation include 
proteases, enzymes involved in nucleic acid metabolism including di- 
hydrufolate reductase and hypoxanthine phosphoribosyl wansferase, 
lipid metabolism and drug aansport mechanisms. The presentation 
wdl focus on malaria, leishmaniasis and trypanosomiasis. Even with 
the discovery of new drugs, it is necessary to begin to develop strate- 
gies for preventing the rapid emergence of resistance since in recent 
experience, drug resistance is emerging faster than drugs are being 
developed. Multidrug resistance mechanisms and drug efflux and se- 
questration models will be discussed and as will strategies for the 
prevention of resistance. 
Any exciting news in the treatment of malaria 
N.J. White. Faulty .f Tropical Medicine, Mahidol University, Bangkok, 
Tkailand 
Although antimalarial drug resistance in both Pfakiparum and I? uivox 
continues to increase several new treatments have been introduced 
in recent years. There is increasing evidence that the artemisinin 
derivatives are safe, and they have proved the most rapidly acting 
of available antimaianals. In severe malaria the artemisinin deriva- 
tives are at least as effective, and better tolerated than parented 
quinine. The challenge now is to determine which is the best of 
the available compounds. In uncomplicated malaria they retain efi- 
cacy against multi-drug resistant saa ins .  In combination with meflo- 
quine the artemisinin derivatives accelerate the treatment response, 
reduce transmission potential, and increase overall cure rates. Two 
new alternative combinations have proved both effective and re- 
markably well tolerated in the treatment of multi-drug resistance 
uncomplicated malaria. These are artemether-benflumetol and ato- 
vaquone-propanil. With these new drugs the spectre of untreatable 
malaria has receded a little. 
I SlOO 1 Leishmaniasis: A Novel Threat to 
lmmunocompromised Patients, a WHO 
Response 
P Desjeux CTD/TRh:  WHO, Geneva, Suntzerland 
The overlappmg of msceral l e i s h a m  (VL) and AIDS IS mcreasing 
due to the spread of the AIDS pandemc m rural areas and that of 
VL m suburban areas Consequently, cases of co-mfected pahents are 
bemg reported more and more hquently, w t h  important chca l ,  
dIagnoshc, chemotherapeuhc, epidemologd and economc m- 
plications. Leishmania/HIV co-infections are regarded as emerging 
diseases, especially in southern Europe, where 25-70% of adult VL 
cases are related to HIV infection, and 1.59% of AIDS cases suffer 
h m  newly acquired or reactivated VL. In the Mediterranean areas, 
VL is the most frequent opportunistic parasitic mfection. There is 
a clear association between VL and severe immunosuppression. In 
southern Europe there is evidence of a sharp reduction of mean 
survival compared with other AIDS patients. The response to treat- 
ment appears to be worse than in HIV-negative patients. Finally VL 
can remain asymptomatic for years but then evolve into a clinical 
disease in case of immunosuppression. The WHO initiative aims at 
the estabhhment of a surveillance system in order to: - improve the 
coordination and exchange of information between the institutions 
involved, - improve the reliability of the epidemiological data, - im- 
prove the diagnosis, treatment and follow up of co-mfected patients 
and improve the active medical surveillance of the main population 
at risk (intravenous drug users). A network was created of 15 in- 
stitutions h m  10 countries. A standardzed case report form and 
guidelines were elaborated and endorsed by the members of the net- 
work. Finally a central international registxy was set up at WHO to 
centralize, process and a s e  the worldwide information periodi- 
cally. Data concerning 692 retrospective cases are presented here. 
ml The Trials and Tribulations of Developing New 
W E. Gutteridge. Glaxo Welhme Research and Development, 
Beckenham, UK, World Health Organization, Geneua, Switzerland 
Pharmaceutical research and development is scientlfically and tech- 
nically demanding. Hence the process is expensive, time-consuming 
and highly speculative, and successful new products are intrinsically 
expensive. First hand experience of the discovery and development, 
just completed, of the antimalarial fixed combination, atovaquone 
+ propanil, will be reviewed to illustrate just how demanding the 
process can be. Options to deal with the fact that the resulting new 
product is unal€ordable by most patients requiring treatment in dis- 
ease-endemic countries will be described. Finally, current efforts 
within the UNDP/World Bank/WHO Special Programme for Re- 
search and Training in Tropical Diseases (TDR) to form &ance(s) 
with the private pharmaceutical sector to maintain a flow of new 
products for tropical diseases will be summarised. 
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F] Impact of Pediatric Respiratory Tract Infections 
and Parental Attitudes to Antibiotic Prescribing 
U.B. Schaad. Department ofpediatrics, University o f k e l ,  Basel, 
Switzerland 
Worldwide, in both pediatric and adult patients. respiratory tract in- 
fections are the most common infectious diseases. The majority of 
rcspiratory infections are caused by viruses. For the physicians in- 
volved, the major diagnostic challenge is to diagnose promptly the 
bacterial cases, which can occur as primary or superimposed in- 
fections. Correct diagnosis is important because spec& antibiotic 
therapy is effective against bacterial respiratory tract infections, but 
excessive antibiotic use for respiratory infections induces resistance. 
Prompt and reliable dqnosis is principally based on the clinical 
findings and a few investigations (microbiological, radiological, lab- 
oratory), accordmg to the site of mfection. 
